Oramed Pharmaceuticals Inc. (ORMP)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Currency in USD
Valuation measures4
| Market cap (intra-day) | 95.02M |
| Enterprise value | -15.41M |
| Trailing P/E | 16.75 |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 70.99 |
| Price/book (mrq) | 0.58 |
| Enterprise value/revenue | -11.50 |
| Enterprise value/EBITDA | -2.10 |
Trading information
Stock price history
| Beta (5Y monthly) | 1.82 |
| 52-week change 3 | -15.83% |
| S&P500 52-week change 3 | 21.33% |
| 52-week high 3 | 5.2500 |
| 52-week low 3 | 1.6700 |
| 50-day moving average 3 | 2.7898 |
| 200-day moving average 3 | 2.6339 |
Share statistics
| Avg vol (3-month) 3 | 150.8k |
| Avg vol (10-day) 3 | 85.48k |
| Shares outstanding 5 | 40.52M |
| Implied shares outstanding 6 | 40.52M |
| Float 8 | 36.7M |
| % held by insiders 1 | 11.30% |
| % held by institutions 1 | 12.88% |
| Shares short (15 Apr 2024) 4 | 367.6k |
| Short ratio (15 Apr 2024) 4 | 3.11 |
| Short % of float (15 Apr 2024) 4 | 1.00% |
| Short % of shares outstanding (15 Apr 2024) 4 | 0.91% |
| Shares short (prior month 15 Mar 2024) 4 | 484.01k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:12 |
| Last split date 3 | 23 Jan 2013 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 412.31% |
| Operating margin (ttm) | -1,176.79% |
Management effectiveness
| Return on assets (ttm) | -5.16% |
| Return on equity (ttm) | 3.24% |
Income statement
| Revenue (ttm) | 1.34M |
| Revenue per share (ttm) | 0.03 |
| Quarterly revenue growth (yoy) | -100.00% |
| Gross profit (ttm) | N/A |
| EBITDA | -15.57M |
| Net income avi to common (ttm) | 5.53M |
| Diluted EPS (ttm) | 0.1400 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 162.05M |
| Total cash per share (mrq) | 4 |
| Total debt (mrq) | 51.62M |
| Total debt/equity (mrq) | 31.69% |
| Current ratio (mrq) | 3.06 |
| Book value per share (mrq) | 4.06 |
Cash flow statement
| Operating cash flow (ttm) | -10.29M |
| Levered free cash flow (ttm) | -9.69M |
© 2024 Yahoo. All rights reserved.